US Patent Issued to Bristol-Myers Squibb on March 3 for "LAG-3 antagonist therapy for lung cancer" (New Jersey Inventors)

ALEXANDRIA, Va., March 3 -- United States Patent no. 12,565,528, issued on March 3, was assigned to Bristol-Myers Squibb Co. (Princeton, N.J.).

"LAG-3 antagonist therapy for lung cancer" was invented by Laurence David Toms (Princeton, N.J.) and Paul Andrew Basciano (Princeton, N.J.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The disclosure provides a method of treating a human subject afflicted with lung cancer with a lymphocyte activation gene-3 (LAG-3) antagonist. In some aspects, the method comprises combination of the LAG-3 antagonist with an additional therapeutic agent (e.g., a programmed death-1 pathway inhibitor) and/or anti-cancer therapy (e.g., chemotherapy such as a platinum doublet chemotherap...